| Literature DB >> 27560112 |
M Adamiak1, A Abdelbaset-Ismail1, M Kucia1,2, J Ratajczak1, M Z Ratajczak1,2.
Abstract
Entities:
Mesh:
Substances:
Year: 2016 PMID: 27560112 PMCID: PMC5143204 DOI: 10.1038/leu.2016.236
Source DB: PubMed Journal: Leukemia ISSN: 0887-6924 Impact factor: 11.528
Figure 1MyD88-KO mice are easily mobilized by G-CSF and AMD3100. MyD88-deficient and WT mice (as control) were treated with G-CSF (for 6 days at 100 μg/kg per day, subcutaneous injection, upper panel) and AMD3100 (single dose at 5 μg/kg, intraperitoneal injection, lower panel). Experimental mice were killed 6 h after the last G-CSF injection and 1 h after AMD3100 mobilization, and the numbers of WBCs, SKL (Sca-1+ c-kit+ Lin−) cells, HSCs (Sca-1+ CD45+ Lin−) and CFU-GM clonogenic progenitors from PB were evaluated. Results from two separate experiments are pooled together (n=8 mice per group). *P<0.05.
Figure 2The level of HO-1 was evaluated in BMMNCs, and sorted Sca-1+ cells collected from WT and MyD88-KO mice were stimulated with G-CSF (140 ng/ml) or AMD3100 (140 ng/ml). Left panel: expression of HO-1 at the mRNA level by real-time PCR. Results from three independent experiments are pooled together and shown as the percentage of expression in WT mice. *P⩽0.05. Right panel: expression of HO-1 by western blotting in BMMNCs and Sca-1+ cells purified from WT and MyD88-KO mice. As shown here, the cells from MyD88-KO mice show downregulation of HO-1 compared with WT-derived cells. The experiment was carried out twice with similar results, and a representative blot is shown.